Optimal Velocity and Safety of Discontinuous Conduction through the Heterogeneous Purkinje-Ventricular Junction

被引:52
|
作者
Aslanidi, Oleg V. [1 ]
Stewart, Philip [1 ]
Boyett, Mark R. [2 ]
Zhang, Henggui [1 ]
机构
[1] Univ Manchester, Biol Phys Grp, Sch Phys & Astron, Manchester, Lancs, England
[2] Univ Manchester, Cardiovasc Res Grp, Fac Med & Human Sci, Manchester, Lancs, England
基金
英国生物技术与生命科学研究理事会; 英国工程与自然科学研究理事会;
关键词
ACTION-POTENTIAL CONDUCTION; FIBER-MUSCLE JUNCTIONS; SODIUM CURRENT I-NA2; SLOW CONDUCTION; CARDIAC TISSUE; CANINE VENTRICLE; DOG HEART; PROPAGATION; CELLS; CALCIUM;
D O I
10.1016/j.bpj.2009.03.061
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Slow and discontinuous wave conduction through nonuniform junctions in cardiac tissues is generally considered unsafe and proarrythmogenic. However, the relationships between tissue structure, wave conduction velocity, and safety at such junctions are unknown. We have developed a structurally and electrophysiologically detailed model of the canine Purkinje-ventricular junction (PVJ) and varied its heterogeneity parameters to determine such relationships. We show that neither very fast nor very slow conduction is safe, and there exists an optimal velocity that provides the maximum safety factor for conduction through the junction. The resultant conduction time delay across the PVJ is a natural consequence of the electrophysiological and morphological differences between the Purkinje fiber and ventricular tissue. The delay allows the PVJ to accumulate and pass sufficient charge to excite the adjacent ventricular tissue, but is not long enough for the source-to-load mismatch at the junction to be enhanced over time. The observed relationships between the conduction velocity and safety factor can provide new insights into optimal conditions for wave propagation through nonuniform junctions between various cardiac tissues.
引用
收藏
页码:20 / 39
页数:20
相关论文
共 26 条
  • [21] EFFECTS OF ANTIARRHYTHMIC DRUGS ON THE CONDUCTION THROUGH PURKINJE-FIBERS AND VENTRICULAR MUSCLE - A CLASSIFICATION OF ANTIARRHYTHMIC DRUGS
    TSUTSUMI, T
    SATO, T
    SEKIYA, S
    YAZAKI, Y
    HARUMI, K
    CURRENT TOPICS IN ANTIARRHYTHMIC AGENTS: MODE OF ACTION AND CLINICAL USAGE, 1989, 56 : 213 - 216
  • [22] Conduction velocity and gap junction resistance in hypertrophied, hypoxic guinea-pig left ventricular myocardium
    Cooklin, M
    Wallis, WRJ
    Sheridan, DJ
    Fry, CH
    EXPERIMENTAL PHYSIOLOGY, 1998, 83 (06) : 763 - 770
  • [23] Pro-Arrhythmic Effects of Discontinuous Conduction at the Purkinje Fiber-Ventricle Junction Arising From Heart Failure-Induced Ionic Remodeling - Insights From Computational Modelling
    Jian, Kun
    Li, Chen
    Hancox, Jules C.
    Zhang, Henggui
    FRONTIERS IN PHYSIOLOGY, 2022, 13
  • [24] Gap junction modifier rotigaptide decreases the susceptibility to ventricular arrhythmia by enhancing conduction velocity and suppressing discordant alternans during therapeutic hypothermia in isolated rabbit hearts
    Hsieh, Yu-Cheng
    Lin, Jiunn-Cherng
    Hung, Chen-Ying
    Li, Cheng-Hung
    Lin, Shien-Fong
    Yeh, Hung-I
    Huang, Jin-Long
    Lo, Chu-Pin
    Haugan, Ketil
    Larsen, Bjarne D.
    Wu, Tsu-Juey
    HEART RHYTHM, 2016, 13 (01) : 251 - 261
  • [25] Gap junction inhibition by heptanol increases ventricular arrhythmogenicity by reducing conduction velocity without affecting repolarization properties or myocardial refractoriness in Langendorff-perfused mouse hearts
    Tse, Gary
    Yeo, Jie Ming
    Tse, Vivian
    Kwan, Joseph
    Sun, Bing
    MOLECULAR MEDICINE REPORTS, 2016, 14 (05) : 4069 - 4074
  • [26] Chronic amiodarone attenuates premature stimulation-induced perturbation of ventricular repolarization through the modulation of action potential duration and conduction velocity restitution
    Osaka, T
    Yokoyama, E
    Harada, M
    Takemoto, Y
    Suzuki, T
    Ito, A
    Kodama, I
    CIRCULATION, 2005, 112 (17) : U387 - U387